On Friday, Shares of Micron Technology, Inc. (NASDAQ:MU), remained flat at $24.47.
Analysts at Topeka Capital Markets earlier upgraded Micron Technology, to “buy” from “hold” and raised their price target to $34 from $30.
After meeting with the administration, analysts were encouraged by likely outsized DRAM cost per bit improvement relative to competitors, steady TLC 3D NAND progress that can drive a demand inflection and continued commitment to capital returns while maintaining a competitive capex level, according to Barron’s.
“We believe MU is at or ahead of plan in its 20nm DRAM ramp,” analysts said. “We expect administration to accomplish this critical transition while keeping DRAM capex flattish.”
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
Shares of Goodrich Petroleum Corp. (NYSE:GDP), declined -10.23% to $1.58, during its last trading session, hitting its lowest level.
Today, Goodrich Petroleum Corporation, declared that it has commenced completion operations on two of its six drilled but unaccomplished wells in the Tuscaloosa Marine Shale (“TMS”). The B-Nez 43H-1 (70%WI) and B-Nez 43H-2 (74% WI) wells in Tangipahoa Parish are near completion of fracture stimulation, with flow back and initial production predictable within 1 - 2 weeks. The Company presently anticipates concluding the remaining four drilled but unaccomplished TMS wells from mid-July through early September. All six wells, which are located within the Company’s core acreage position of 150,000 net acres, will be accomplished preceding to the fall borrowing base redetermination planned for October 2015.
The Company’s full year capital expenditure budget of $90 - 110 million was front-end loaded, with about 46% of the budget at the mid-point of guidance spent in the first quarter, as the Company entered the year with three rigs under contract. The Company presently has zero rigs running with plans to bring a rig back to the TMS in October, with no change to formerly issued guidance. The Company re-affirms second quarter capital expenditure guidance of $10 – 15 million and exited the first quarter with in excess of $100 million of liquidity. The Company maintains the ability to enhance liquidity by pursuing a potential joint venture or sale of its Eagle Ford Shale asset.
Goodrich Petroleum Corporation, an independent oil and natural gas company, engages in the exploration, development, and production of oil and natural gas. The company holds interest in the Tuscaloosa Marine Shale located in southwest Mississippi and southeast Louisiana; the Eagle Ford Shale Trend located in South Texas; and the Haynesville Shale Trend in Northwest Louisiana and East Texas.
Finally, Bristol-Myers Squibb Company (NYSE:BMY), ended its last trade with 0.27% gain, and closed at $66.80.
Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned by Allied Minds (ALM.L) and Bristol-Myers Squibb Company, declared that it has reached a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitman’s lab at the Harvard School of Dental Medicine.
Malcolm Whitman, PhD, Professor of Developmental Biology, and Tracy Keller, PhD, an instructor in the Department of Developmental Biology, have identified the mechanism of action behind a known natural product, halofuginone (HF). HF is a chemical compound based on an active ingredient in the root of the blue evergreen hydrangea (Dichroa febrifuga), which has been used in traditional Chinese medicine for centuries.
Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children’s Hospital, Professor Whitman’s lab, in partnership with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction (AAR) response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions counting fibrotic and autoimmune diseases.
The licensing agreement with Harvard’s Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitman’s lab will be held by a new ABLS partner specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
